Mode
Text Size
Log in / Sign up
Phase 3 Completed N=127 Randomized Quadruple-blind Treatment

Vitamin D for Established Type 2 Diabetes (DDM2)

Source: ClinicalTrials.gov NCT01736865 ↗
Enrolled (actual)
127
Serious AEs
10.2%
Results posted
Jan 2019
Primary outcomePrimary: Disposition Index — 0.023; 0.149 index
◆ Published Evidence
Established
97citations · ~10 / year
Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation.
The American journal of clinical nutrition · 2016 · Open access · Likely link

Summary

This research study in adults with established type 2 diabetes will test whether daily vitamin D supplementation affects how the body processes glucose (sugar).

Linked Publications (3)

  • Vitamin D status of black and white Americans and changes in vitamin D metabolites after varied doses of vitamin D supplementation.
    The American journal of clinical nutrition · 2016 · 97 citations · Open access · Likely link
  • Effect of vitamin D supplementation on cardiovascular risk in type 2 diabetes.
    Clinical nutrition (Edinburgh, Scotland) · 2019 · 50 citations · Open access · Likely link
  • Exploring the effect of vitamin D3 supplementation on surrogate biomarkers of cholesterol absorption and endogenous synthesis in patients with type 2 diabetes-randomized controlled trial.
    The American journal of clinical nutrition · 2020 · 10 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Disposition Index
0.023; 0.149
SECONDARY
Number of Participants With Change in Glycemia
53; 52

Eligibility Criteria

Inclusion Criteria

  • Established type 2 diabetes, defined by one of the following two criteria:
  • Age ≥ 25 years and ≤ 75 years
  • BMI: 23 to 40 kg/m2 inclusive
  • Provision of signed and dated written informed consent prior to any study procedures.

Major Exclusion Criteria

  • "Severe" diabetes defined by one of the following criteria:
  • - (a) Symptoms of hyperglycemia;
  • - (b) Screening HbA1c ≥ 7.5 [may indicate potential for rapid progression during the trial necessitating need to amplify diabetes-specific pharmacotherapy]
  • History of nephrolithiasis or hypercalcemia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01736865) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search